CAPR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026

Faruqi & Faruqi is investigating potential securities-law claims against Capricor Therapeutics (NASDAQ: CAPR) and is urging investors who bought shares between Dec. 17, 2025 and Jul. 26, 2026 to contact the firm. The firm highlights a Sept. 28, 2026 deadline to seek lead-plaintiff status in a newly filed federal securities class action. While no financial metrics are cited, the litigation overhang is a modest negative for sentiment and could affect near-term positioning.

Analysis

This kind of litigation notice tends to matter more for trading than for enterprise value in the first few weeks: it can widen the discount rate investors apply to a cash-burning biotech, tighten borrow, and pressure any near-term financing discussions. The immediate risk is not the lawsuit itself but the market’s fear that the complaint surfaces a disclosure gap, which can hit multiple compression harder than any direct damages estimate.

The second-order loser is usually the company’s capital access stack. For a name like CAPR, even a modest increase in perceived legal/clinical disclosure risk can make follow-on equity, ATM usage, or partnership negotiations less favorable for 1-3 months; that matters more than the ultimate settlement amount. If the underlying fundamentals remain intact and there is no new regulatory or trial shock, the move can be overdone and mean-revert once the complaint is public and the headline flow fades.

Contrarian view: these reminders often cluster around pre-set deadlines and can be largely promotional unless paired with a concrete new allegation or an SEC action. The market may be pricing “fraud risk” before verifying whether this is a disclosure issue, a clinical readout issue, or simply post-drawdown litigation. For the next 6-18 months, the real falsifier is whether management can preserve cash runway and avoid any follow-on data or guidance surprise that would turn a legal overhang into a financing problem.

Key Decisions for Investors

• Tactically avoid fresh longs in CAPR until the complaint details and company response are public; the upside from relief is likely smaller than the downside from a disclosure shock.
• If borrow is available, consider a small short CAPR vs long XBI pair for 1-4 weeks; the edge is on idiosyncratic legal overhang rather than sector beta.
• If you already own CAPR, use any litigation-driven bounce to reduce exposure ahead of the lead-plaintiff deadline and any amended filings; this is a cleaner risk-management trade than trying to own the headline.
• For options, only consider a bearish structure if implied vol remains below realized headline volatility: a 1-2 month put spread can define risk while targeting a 15-25% downside move if the market prices in incremental disclosure risk.
• Watchlist trigger: if CAPR announces any financing, updated guidance, or SEC inquiry, reassess immediately; that is the point where legal noise can become a fundamental dilution event.